Immunoglobulin Preparations
Immunoglobulin preparations are produced from human blood and contain a number of quite different antibodies (polyclonal antibodies).
Name
|
Marketing Authorisation Holder
|
License Number
|
License Date
|
Use
|
Further Information
|
Privigen
|
Normales Immunglobulin vom Menschen (IVIg)
|
CSL Behring GmbH
|
EU/1/08/446/001-005 |
25.04.2008 |
intravenös |
EPAR: Privigen
|
Panzyga
|
Normales Immunglobulin vom Menschen (IVIg)
|
Octapharma GmbH
|
PEI.H.11786.01.1 |
25.02.2016 |
intravenös |
PharmNet.Bund
|
Octagam 10%
|
Normales Immunglobulin vom Menschen (IVIg)
|
Orifarm GmbH
|
PEI.H.11745.01.1 |
28.06.2017 |
intravenös |
PharmNet.Bund
|
Intratect, 100g/l, Infusionslösung
|
Normales Immunglobulin vom Menschen (IVIg)
|
Biotest Pharma GmbH
|
PEI.H.11631.01.1 |
05.12.2012 |
intravenös |
PharmNet.Bund
|
Ig Vena 50 g/l Infusionslösung
|
Normales Immunglobulin vom Menschen (IVIg)
|
Orifarm GmbH
|
PEI.H.12001.01.1 |
19.08.2019 |
intravenös |
PharmNet.Bund
|
Octagam 5%
|
Normales Immunglobulin vom Menschen (IVIg)
|
Octapharma GmbH
|
PEI.H.11974.01.1 |
11.12.2018 |
intravenös |
PharmNet.Bund
|
Intratect 100 g/l
|
Normales Immunglobulin vom Menschen (IVIg)
|
CC Pharma GmbH
|
PEI.H.11933.01.1 |
19.07.2017 |
intravenös |
PharmNet.Bund
|
Octagam 10%
|
Normales Immunglobulin vom Menschen (IVIg)
|
CC-Pharma GmbH
|
PEI.H.11805.01.1 |
11.12.2015 |
intravenös |
PharmNet.Bund
|
Octagam 10%
|
Normales Immunglobulin vom Menschen (IVIg)
|
Octapharma GmbH
|
PEI.H.03627.01.1 |
20.05.2008 |
intravenös |
PharmNet.Bund
|
Octagam 10%
|
Normales Immunglobulin vom Menschen (IVIg)
|
kohlpharma GmbH
|
PEI.H.11697.02.1 |
24.07.2014 |
intravenös |
PharmNet.Bund
|
Ig Vena 50 g/l Infusionslösung
|
Normales Immunglobulin vom Menschen (IVig)
|
kohlpharma GmbH
|
PEI.H.12138.01.1 |
10.01.2022 |
intravenös |
PharmNet.Bund
|
Yimmugo 100mg/ml
|
Normales Immunglobulin vom Menschen (IVIg)
|
Biotest Pharma GmbH
|
PEI.H.12143.01.1 |
11.11.2022 |
intravenös |
PharmNet.Bund
|
Optiglobin 100 mg/ml
|
Normales Immunglobulin vom Menschen (IVIg)
|
Prothya Biosolutions Netherlands B.V.
|
PEI.H.12033.01.1 |
28.08.2020 |
intravenös |
PharmNet.Bund
|
Cutaquig
|
Normales Immunglobulin vom Menschen (SCIg)
|
Octapharma GmbH
|
PEI.H.11936.01.1 |
28.02.2019 |
subkutan |
PharmNet.Bund
|
Xembify
|
Normales Immunglobulin vom Menschen (SCIg)
|
Instituto Grifols, S.A., E
|
PEI.H.12061.01.1 |
09.12.2021 |
subkutan |
PharmNet.Bund
|
Cuvitru
|
Normales Immunglobulin vom Menschen (SCIg)
|
Takeda GmbH
|
PEI.H.11795.01.1 |
19.07.2016 |
subkutan |
PharmNet.Bund
|
Tetagam P
|
Tetanus-Ig
|
CSL Behring GmbH
|
108a/89 |
22.09.1992 |
intramuskulär |
PharmNet.Bund
|
Berirab
|
Tollwut-Ig
|
CSL Behring GmbH
|
107a/89 |
22.09.1992 |
intramuskulär |
PharmNet.Bund
|
Varitect CP
|
Varicella Zoster-Ig
|
Biotest Pharma GmbH
|
203a/95 |
21.12.1999 |
intravenös |
PharmNet.Bund
|
Disclaimer
The list of medicines contains the products that have a valid marketing authorization. It contains no information as to whether the preparations are available on the market.
The information contained in the Federal Gazette, which is the official publication organ of the Paul-Ehrlich-Institut, is legally binding.
As of: PEI announcement No. 520 in BAnz AT 22.08.2024 B6.
Summary of Product Characteristics (SmPCs) and the Package Leaflet (PL)
Where the European Medicines Agency (EMA) offers further information, you will find a link to the EPAR (European public assessment report) in the table.
If user and technical information or public assessment reports are available in PharmNet.Bund, the Federal and State Pharmaceutical Information Portal, these are directly linked to PharmNet.Bund in the table.